Skip to main content
European Commission logo print header

Magnetic cross-modal brain activity scanner MAX-BAS

Periodic Reporting for period 1 - MAX-BAS (Magnetic cross-modal brain activity scanner MAX-BAS)

Berichtszeitraum: 2019-09-01 bis 2021-08-31

MAX-BAS (Magnetic cross-modal brain activity scanner) project aimed at commercialising the whole-head combined MEG-MRI scanner that was developed in the FET Open project BREAKBEN. The system uses the same superconductor-based detectors for both magnetoencephalography (MEG) and magnetic resonance imaging (MRI) of the brain. This will make it possible to localise brain activity in anatomical structures with unprecedented accuracy while tracking the bursts of activity at millisecond scale. Cross-modal MEG-MRI provides beneficial information for both research and for clinical use. It has the potential to improve the accuracy, reliability, and throughput of functional brain imaging. Ultimately, the goal is to reduce healthcare costs caused by brain disorders, to improve the treatment outcomes and the life quality of the patients, and to increase the understanding about the human brain.
We have developed the prototype further with robust operation and compatibility with hospital environment in mind. We have analysed the market and intellectual property landscape, and validated the problem by interviewing potential customers. We have proposed a business model for bringing cross-modal MEG-MRI scanners to the market. By participating in pitching events and exhibitions, we have been able to attract potential investors. The technology has been presented in a book chapter, and at least five science or technology news sites published online articles based on our press release.
Our whole-head cross-modal MEG-MRI scanner represents the leading edge in superconductor-based MEG technology and pulsed MRI. MEG-MRI has the potential to reduce healthcare costs caused by brain disorders, and to improve the treatment outcomes and the life quality of the patients. It may even enable preventive population-level screening and monitoring processes for brain health. Worldwide, one out of six people suffer from some kind of brain disorder, and in Europe, the annual cost for society is over 800 billion euros, so even modest improvements can lead to substantial savings.